- Open Access
Stereotactic radiosurgery may contribute to overall survival for patients with recurrent head and neck carcinoma
© Kawaguchi et al; licensee BioMed Central Ltd. 2010
Received: 3 March 2010
Accepted: 9 June 2010
Published: 9 June 2010
The aim of this study is to examine the effect of stereotactic radiosurgery (SRS) in the treatment of advanced, recurrent lesions for head and neck carcinoma both with and without lymph node involvement.
Between April 2006 and July 2007, 22 patients (mean age 67 years) with advanced, recurrent head and neck carcinoma were treated with stereotactic radiosurgery. All of the patients except one had biopsy confirmed disease prior to stereotactic radiosurgery. Patients included 3 rT2, 8 rT3, and 9 rT4; 8 of the patients had lymph node metastases. Marginal SRS doses were 20-42 Gy delivered in two to five fractions. Starting one month after SRS, all patients received S-1 oral chemotherapy for one year.
At an overall median follow-up of 24 months (range, 4-39 months), for the 14 locally recurrent patients without lymph node metastases, 9 patients (64.3%) had a complete response (CR), 1 patient (7.1%) had a partial response (PR), 1 patient (7.1%) had stable disease (SD), and 3 patients (21.4%) had progressive disease (PD). For the 8 patients with lymph node metastases, 1 patient with a single retropharyngeal (12.5%) had CR; the remaining 7 patients (87.5%) all progressed. Nine patients have died from their cancer. The overall actuarial 2-year survival for the patients with and without lymph node metastases is 12.5% and 78.6%, respectively.
These results show the benefit of stereotactic radiosurgery salvage treatment for advanced, recurrent lesions, without lymph node metastases in previously irradiated head and neck cancer.
The majority of head and neck region squamous cell carcinomas present at an advanced stage and are treated with a combined-modality approach that often includes surgery, radiation therapy, and chemotherapy. Despite such aggressive approaches, advanced squamous cell carcinoma of the head and neck tends to recur locoregionally and, thus, presents a significant clinical challenge [1–3]. Surgery and/or conventional chemoradiotherapy salvage is difficult in advanced, recurrent lesions of head and neck carcinoma given the proximity of critical organs. Similarly, radical treatment for wide recurrent lesions is limited by overall radiation doses for the body and the possibility of severe post-operative dysfunction. In cases where further surgery is not feasible, reirradiation offers the potential to gain locoregional control and achieve palliation .
Several studies have confirmed the feasibility of reirradiation of recurrent head and neck tumors, with curative intent using external beam radiation therapy (EBRT) [5–8]. More recently, stereotactic radiosurgery (SRS) has been employed in the treatment of head and neck cancers both in primary cases [9, 10] and in recurrent cases [11–15]. The CyberKnife® (Accuray Incorporated, Sunnyvale, California, USA) is a frameless robotic radiosurgery system that has been utilized by numerous clinicians around the world to treat intracranial and extracranial tumors [9, 13, 16, 17]. The CyberKnife image-guided radiosurgical system can deliver isocentric or non-isocentric beams with high precision and high dose conformity . These abilities are especially important when treating irregularly shaped tumors, or those in difficult locations close to critical structures, as is the case with many of the patients with advanced, recurrent head and neck cancer. Here, we report on the tumor response and overall survival of stereotactic radiosurgery treatment using the CyberKnife for advanced, recurrent head and neck carcinoma lesions both with and without lymph node metastases.
Between April 2006 and July 2007, 22 patients with advanced, recurrent head and neck squamous cell carcinoma were treated at the Yokohama CyberKnife Center, Yokohama, Japan. All patients included in this study completed an informed consent form. Patients were examined using PET-CT, MRI, and Ultrasound. Prior to radiation therapy, biopsies were performed for all patients, except for one for whom the recurrence was located deep in their temple muscle. For that patient, diagnosis was determined based upon the high level of uptake observed on PET scan. We assumed that this was a metastasis from the original squamous cell carcinoma that was located on the floor of their oral cavity. Hence, we denoted this patient as M1.
Surgery + Post-operative Chemo-Radiation
Prior radiation dose (Gy)
Total (daily) dose range
Squamous cell carcinoma
Regions of recurrence or metastases
Limited with lymph node
Treatment Characteristics: Summary of treatment dose and treated tumor volume.
Number of Patients (%)
20 - 29
30 - 34
35 - 39
40 - 42
Tumor volume (cm 3 )
3.4 - 74.4
Tumor diameter (mm)
15.21 - 58.65
In addition to stereotactic radiosurgery, a low dose of oral chemotherapy S-1 (oral 5-FU prodrug) (Taiho Pharmaceutical Company Limited, Tokyo, Japan) was administered to control micro-lymph node metastases and distant metastases. The S-1 treatment began one month after SRS and consisted of 40-80 mg/body of S-1 for 2 weeks followed by a one week break; the treatment sequence was repeated for one year.
Following stereotactic radiosurgery, patients were monitored at either Tsurumi University Hospital or Toshiba Rinkan Hospital by oral and maxillofacial surgeons and at Yokohama CyberKnife Center by radiation oncologists. The clinical follow-up interval was every 2 weeks for the first 3 months, and every 4 weeks thereafter until the patient reached 2 years follow-up. Treatment outcome was assessed based on the Response Evaluation Criteria in Solid Tumors (RECIST) . Response to treatment was evaluated using MRI at one month follow-up, contrast-enhanced CT at two months follow-up, PET-CT and MRI at three months follow-up, and MRI or PET-CT every three months thereafter. Toxicities were graded using the National Cancer Institute Common Toxicity Criteria Scale, Version 3.0. Overall survival after stereotactic radiosurgery was determined by Kaplan-Meier survival analysis.
Twenty-two advanced, recurrent head and neck cancer patients were treated with SRS. In these advanced, recurrent patients treatment options were limited and the decision to treat these patients with SRS was based upon a variety of issues including the nature of the tumor recurrence, prior treatment approaches and patient preference. Specifically, the recurrent tumors were solid masses that were well suited to a radiosurgical treatment given the proximity of critical organs. For those patients that previously received conventional radiotherapy (14/22), the ability to target the radiation dose specifically to the tumor and limit the dose to surrounding, previously irradiated, tissue was also a strong indicator for SRS. Lastly, the patients strongly preferred a treatment option that did not require hospitalization.
The majority of patients (12/22) received SRS treatment as outpatients with curative intent. Ten patients (45%), however, received treatment with palliative intent while in terminal care at the hospital. At an overall median follow-up of 24 months (range, 4-39 months), 9 patients have died from their cancer. One additional patient died from acute cardiac insufficiency. For surviving patients, the median follow-up was 32 months (range, 27-39 months).
Clinical Outcomes: Summary of tumor response by RESIST criteria.
Number of Patients (%)
The first month following SRS 17 patients (77.3%) experienced Grade 2 xerostomia and decreased taste; 5 patients (22.7%), all of which were rT4 cases, experienced Grade 3 xerostomia and decreased taste. Of the 5 patients that experienced Grade 3 toxicity, one received prior radiation therapy (total dose 65 Gy) and four received prior surgery followed by radiation therapy (total dose 50-56 Gy). After the two month follow-up, there have been no serious complications associated with the SRS re-irradiation. Fourteen of the patients who had previously received external beam radiation experienced Grade 1 (11 patients) and Grade 2 (3 patients) osteoradionecrosis at 10-18 months after SRS. None of the surgery-only patients experienced any late complications.
Our results demonstrate that CyberKnife frameless stereotactic radiosurgery for patients with recurrent head and neck carcinoma is feasible and safe in the setting of previous irradiation. In the case of local recurrence without lymph node metastases, 9 out of 14 (64.3%) patients had a complete response with a 2-year overall survival rate of 78.6%. Overall, 10 out of 22 (45.5%) of the advanced, recurrent patients maintain a complete response at a median 2-years follow-up.
Overview of prior stereotactic radiosurgery results for the reirradiation of recurrent head and neck carcinoma.
SRS median total dose/fx
Follow-up median, range (months)
Tumor size median, range (cc)
Prior irradiation Dose, median, range (Gy)
Complete Response Rate
Voynov et al. 
97.8, 70.1-190.3 (BED10)
No Grade 4+
22% at 2-yrs
Heron et al. 
No Grade 3+
18% at 1-yr
Roh et al. 
No Grade 4+ 36% Grade 3
52.1% at 1-yr, 30.9% at 2-yrs
Rwigema et al. 
No Grade 4+ 4.7% Grade 3
48% at 1-yr, 16% at 2-yrs
Sulman et al. 
IMRT 60 Gy
20% severe Including 1% Grade 5
58% at 2-yrs
Siddiqui et al. 
13-18/1 or 36-48/5-8
6.7% Grade 3‡ 9% Grade 4‡
38.1% at 1-yr 14.3% at 2-yrs
Unger et al. 
11% Grade 4+
41% at 2-yrs
22 (14 N-, 8 N+)
No Grade 4+ 22.7% Grade 3
45.4% (N- 64.3%, N+ 12.5%)
N- 78.6% at 2-yrs N+ 12.5% at 2-yrs
Another factor affecting the reported overall survival rates is the use of chemotherapy. Recent evidence suggests that concurrent administration of chemotherapy may reduce the risk of micrometastases. A study of nasopharyngeal carcinoma demonstrated that progression-free survival among the patients who were treated with radiation alone was 24% at 3 years, compared to 69% in the combined treatment group . In our study, starting one month post-SRS and continuing for one year, 100% (22/22) of the patients received low dose S-1 oral chemotherapy to maintain local control and to avoid lymph node and distant metastases. We choose to use S-1, an oral 5-fluorouracil (5-FU), based on several studies showing promising safety and efficacy results with this chemotherapy agent for the treatment of advanced head and neck squamous cell carcinoma [27–30]. This addition of S-1 to the SRS treatment may have also contributed to the satisfactory outcomes observed in this study.
While our results are very promising for cases without lymph node metastases, in the cases with lymph node metastases only 1 of 8 patients had a complete response and the 2-year overall survival rate was 12.5%. Since these lymph node metastases were mostly locally advanced lesions, neck dissection was not available. Given the low observed control rate, we recommend that patients eligible for surgery under general anesthesia undergo a combined salvage treatment strategy of neck dissection for the regional lymph node metastases and SRS for the locally recurrent lesion.
Reported toxicity rates for reirradiation of recurrent head and neck carcinoma include late Grade 4 and higher toxicity rates of 9%  and 11% , a rate of 36% Grade 3 toxicity , and a rate of 20% severe toxicity including 1% Grade 5 toxicity for an IMRT reirradiation study . In comparison, our 22.7% rate of Grade 3 toxicity with no higher grade toxicities is promising.
At a median 2-years follow-up, 45.5% (10/22) of the advanced recurrent patients maintained a complete response. For the local recurrent patients with non-lymph node metastases 64.3% (9/14) of patients had a complete response and the 2-year actuarial overall survival rate is 78.6%. Toxicity was acceptable with no observed grade 4 or higher toxicity. Hypofractionated robotic stereotactic CyberKnife radiosurgery treatment is feasible, safe, and well-tolerated for patients with local recurrence in head and neck carcinoma.
Conflict of interests statement
The authors declare that they have no competing interests.
- Chuang SC, Scelo G, Tonita JM, et al.: Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. Int J Cancer 2008, 123: 2390-2396. 10.1002/ijc.23798View ArticlePubMedGoogle Scholar
- Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med 2001, 345: 1890-1900. 10.1056/NEJMra001375View ArticlePubMedGoogle Scholar
- Licitra L, Vermorken JB: Is there still a role for neoadjuvant chemotherapy in head and neck cancer? Ann Oncol 2004, 15: 7-11. 10.1093/annonc/mdh001View ArticlePubMedGoogle Scholar
- De Crevoisier R, Bourhis J, Eschwege F: Modified fractionated radiotherapy in head and neck squamous cell carcinoma (HNSCC) & re-irradiation in recurrent head and neck carcinomas. Cancer Treat Res 2003, 114: 199-212. full_textView ArticlePubMedGoogle Scholar
- Kramer NM, Horwitz EM, Cheng J, et al.: Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005, 27: 406-414. 10.1002/hed.20163View ArticlePubMedGoogle Scholar
- Spencer S, Wheeler R, Peters G, et al.: Phase 1 trial of combined chemotherapy and reirradiation for recurrent unresectable head and neck cancer. Head Neck 2003, 25: 118-122. 10.1002/hed.10178View ArticlePubMedGoogle Scholar
- Oksuz DC, Meral G, Uzel O, Cagatay P, Turkan S: Reirradiation for locally recurrent nasopharyngeal carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys 2004, 60: 388-394. 10.1016/j.ijrobp.2004.03.021View ArticlePubMedGoogle Scholar
- Yu KH, Leung SF, Tung SY, et al.: Survival outcome of patients with nasopharyngeal carcinoma with first local failure: a study by the Hong Kong Nasopharyngeal Carcinoma Study Group. Head Neck 2005, 27: 397-405. 10.1002/hed.20161View ArticlePubMedGoogle Scholar
- Tate DJ, Adler JR Jr, Chang SD, et al.: Stereotactic radiosurgical boost following radiotherapy in primary nasopharyngeal carcinoma: impact on local control. Int J Radiat Oncol Biol Phys 1999, 45: 915-921. 10.1016/S0360-3016(99)00296-5View ArticlePubMedGoogle Scholar
- Kawaguchi K, Yamada H, Horie A, Sato K: Radiosurgical treatment of maxillary squamous cell carcinoma. Int J Oral Maxillofac Surg 2009, 38: 1205-1207. 10.1016/j.ijom.2009.06.003View ArticlePubMedGoogle Scholar
- Pai PC, Chuang CC, Wei KC, et al.: Stereotactic radiosurgery for locally recurrent nasopharyngeal carcinoma. Head Neck 2002, 24: 748-753. 10.1002/hed.10116View ArticlePubMedGoogle Scholar
- Low JS, Chua ET, Gao F, Wee JT: Stereotactic radiosurgery plus intracavitary irradiation in the salvage of nasopharyngeal carcinoma. Head Neck 2006, 28: 321-329. 10.1002/hed.20338View ArticlePubMedGoogle Scholar
- Voynov G, Heron DE, Burton S, et al.: Frameless stereotactic radiosurgery for recurrent head and neck carcinoma. Technol Cancer Res Treat 2006, 5: 529-535.View ArticlePubMedGoogle Scholar
- Roh KW, Jang JS, Kim MS, et al.: Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys 2009, 74: 1348-1355. 10.1016/j.ijrobp.2008.10.013View ArticlePubMedGoogle Scholar
- Heron DE, Ferris RL, Karamouzis M, et al.: Stereotactic Body Radiotherapy for Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Phase I Dose-Escalation Trial. Int J Radiat Oncol Biol Phys 2009.Google Scholar
- Le QT, Tate D, Koong A, et al.: Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2003, 56: 1046-1054. 10.1016/S0360-3016(03)00117-2View ArticlePubMedGoogle Scholar
- Jansen EP, Keus RB, Hilgers FJ, et al.: Does the combination of radiotherapy and debulking surgery favor survival in paranasal sinus carcinoma? Int J Radiat Oncol Biol Phys 2000, 48: 27-35. 10.1016/S0360-3016(00)00594-0View ArticlePubMedGoogle Scholar
- Fu D, Kuduvalli G: A fast, accurate, and automatic 2D-3D image registration for image-guided cranial radiosurgery. Med Phys 2008, 35: 2180-2194. 10.1118/1.2903431View ArticlePubMedGoogle Scholar
- Antypas C, Pantelis E: Performance evaluation of a CyberKnife G4 image-guided robotic stereotactic radiosurgery system. Phys Med Biol 2008, 53: 4697-4718. 10.1088/0031-9155/53/17/016View ArticlePubMedGoogle Scholar
- Romanelli P, Schaal DW, Adler JR: Image-guided radiosurgical ablation of intra- and extra-cranial lesions. Technol Cancer Res Treat 2006, 5: 421-428.View ArticlePubMedGoogle Scholar
- Hara W, Soltys SG, Gibbs IC: CyberKnife robotic radiosurgery system for tumor treatment. Expert Rev Anticancer Ther 2007, 7: 1507-1515. 10.1586/14737126.96.36.1997View ArticlePubMedGoogle Scholar
- Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92: 205-216. 10.1093/jnci/92.3.205View ArticlePubMedGoogle Scholar
- Rwigema JC, Heron DE, Ferris RL, et al.: Fractionated Stereotactic Body Radiation Therapy in the Treatment of Previously-Irradiated Recurrent Head and Neck Carcinoma: Updated Report of the University of Pittsburgh Experience. Am J Clin Oncol 2009.Google Scholar
- Unger KR, Lominska CE, Deeken JF, et al.: Fractionated Stereotactic Radiosurgery for Reirradiation of Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 2010, in press.Google Scholar
- Siddiqui F, Patel M, Khan M, et al.: Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys 2009, 74: 1047-1053. 10.1016/j.ijrobp.2008.09.022View ArticlePubMedGoogle Scholar
- Agulnik M, Epstein JB: Nasopharyngeal carcinoma: current management, future directions and dental implications. Oral Oncol 2008, 44: 617-627. 10.1016/j.oraloncology.2007.08.003View ArticlePubMedGoogle Scholar
- Tsukuda M, Kida A, Fujii M, et al.: [Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer]. Gan To Kagaku Ryoho 2007, 34: 1215-1225.PubMedGoogle Scholar
- Yamashita T, Shinden S, Watabe T, Shiotani A: Outpatient chemotherapy with S-1 for recurrent head and neck cancer. Anticancer Res 2009, 29: 577-581.PubMedGoogle Scholar
- Suzuki S, Ishikawa K: Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother 2009, 15: 335-339. 10.1007/s10156-009-0712-xView ArticlePubMedGoogle Scholar
- Kawasaki M, Watanabe K, Watanabe J: [TS-1 and irradiation combination therapy for head and neck cancer]. Gan To Kagaku Ryoho 2006, 33: 1077-1080.PubMedGoogle Scholar
- Sulman EP, Schwartz DL, Le TT, et al.: IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Int J Radiat Oncol Biol Phys 2009, 73: 399-409. 10.1016/j.ijrobp.2008.04.021View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.